Supplementary Materials

Supplementary Material for:

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Philipp Müller,* Matthias Kreuzaler, Tarik Khan, Daniela S. Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Nitz, Oleg Gluz, Michael von Bergwelt-Baildon, Hans Kreipe, Sai Reddy, Matthias Christgen, Alfred Zippelius*

*Corresponding author. E-mail: ph.mueller{at} (P.M.); alfred.zippelius{at} (A.Z.)

Published 25 November 2015, Sci. Transl. Med. 7, 315ra188 (2015)
DOI: 10.1126/scitranslmed.aac4925

This PDF file includes:

  • Fig. S1. Effect of ansamitocin P3 and DM1 on the maturation of DCs.
  • Fig. S2. CD8/CD4 ratios in human breast tumors before and after T-DM1 monotherapy.
  • Fig. S3. H&E staining of treated Fo5 tumors.
  • Fig. S4. Patterns of intratumoral immune cell subsets after T-DM1 therapy.
  • Fig. S5. Tumor growth and tumor-infiltrating immune cell subsets in mice receiving trastuzumab instead of T-DM1.
  • Fig. S6. Luminex-based cytokine and growth factor measurement in T-DM1– and α-CTLA-4/PD-1–treated tumors.
  • Fig. S7. T cell function in mice receiving trastuzumab instead of T-DM1.
  • Fig. S8. Helios expression, CD8/CD4 and CD8/Treg ratios, and splenic Tregs.
  • Fig. S9. Helios expression and Tregs in mice receiving trastuzumab instead of TDM1.

[Download PDF]